PRL and adenoma: However, given the observed differences in adenoma size and prolactin levels between female and male patients, a crucial question is how the gender-differences in both the average biomarker (prolactin) value and the observed outcomes affects the sample estimate of an optimal threshold, its uncertainty and—importantly—its reliability.